Replies to post #180846 on Avid Bioservices Inc (CDMO)

[until2000]

The plan,

Conduct phase 3 testing of Bavituximab against Nsclc. Going along quite well from all indications.

Most everything else is just speculation, positive or negative.

Time will tell.